| 6.05 0.03 (0.5%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.63 |
1-year : | 8.22 |
| Resists | First : | 6.53 |
Second : | 7.04 |
| Pivot price | 6.39 |
|||
| Supports | First : | 5.71 | Second : | 4.75 |
| MAs | MA(5) : | 6.18 |
MA(20) : | 6.3  |
| MA(100) : | 5.19 |
MA(250) : | 4.39 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 24.2 |
| RSI | RSI(14): 45.3 |
|||
| 52-week | High : | 7.98 | Low : | 2.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IVA ] has closed above bottom band by 20.9%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.4 - 6.44 | 6.44 - 6.48 |
| Low: | 5.91 - 5.96 | 5.96 - 6.01 |
| Close: | 5.97 - 6.05 | 6.05 - 6.13 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Fri, 27 Feb 2026
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect? - Zacks Investment Research
Fri, 20 Feb 2026
Inventiva S.A. (IVA) Stock Analysis: Biotech Breakthroughs With 131% Potential Upside - DirectorsTalk Interviews
Wed, 18 Feb 2026
ANDERA PARTNERS's Inventiva SA(IVA) Holding History - GuruFocus
Tue, 17 Feb 2026
Inventiva (Nasdaq: IVA) reports 2025 prelims and cash runway into 2027 - Stock Titan
Tue, 17 Feb 2026
[SCHEDULE 13G/A] Inventiva S.A. Amended Passive Investment Disclosure - Stock Titan
Wed, 11 Feb 2026
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Increase in Short Interest - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 206 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 35.5 (%) |
| Shares Short | 631 (K) |
| Shares Short P.Month | 116 (K) |
| EPS | -4.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | -991.9 % |
| Return on Assets (ttm) | -56.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 105.1 % |
| Gross Profit (p.s.) | 0.07 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -1.36 |
| PEG Ratio | 0 |
| Price to Book value | -75.63 |
| Price to Sales | 73.56 |
| Price to Cash Flow | -13.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|